/
JBIO
$22.11+$0.11 (+0.50%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.3B
61M shares
52-week range
$6.67 – $28.00
72% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.65%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$11.97
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.0K | $15.0K | $68.0K | $96.0K | $282.0K | $0 |
| Gross profit | −$1.0K | −$15.0K | −$68.0K | −$96.0K | −$282.0K | $0 |
| Gross margin | — | — | — | — | — | — |
| R&D | $7.9M | $15.0M | $38.6M | $64.2M | $53.2M | $93.1M |
| Operating income | −$8.9M | −$23.0M | −$53.2M | −$81.4M | −$74.6M | −$113.5M |
| EBITDA | −$9.5M | −$22.9M | −$51.4M | −$75.4M | −$69.3M | −$127.3M |
| Net income | −$9.6M | −$23.0M | −$51.5M | −$75.5M | −$69.6M | −$127.4M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -14.00 | -32.96 | -73.67 | -100.38 | -85.26 | -4.06 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-2.62 | $-2.74–$-2.53 | 5 |
| 2027 | $0 | $-2.61 | $-2.72–$-2.49 | 5 |
| 2028 | $0 | $-2.56 | $-3.17–$-2.04 | 7 |
| 2029 | $0 | $-2.86 | $-2.86–$-2.86 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.74
Price
$22.11
Implied downside
-88%
Peer comparison
Jade Biosciences, Inc. Common Stock
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
www.jadebiosciences.com- Employees
- 55
- IPO / List date
- Apr 29, 2025
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds JBIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 135,039 | $1.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded JBIO yet.
